TABLE 1

Characteristics of patients with and without periportal steatosis on MRI

Patient 1Patient 2Patient 3Patient 4
Periportal steatosis evident on MRIYesYesNoNo
Dose 1 (IEq/kg)8,5008,82812,7688,544
Dose 2 (IEq/kg)5,3658,333NANA
Packed cell volume of infusion 1 (ml)554.95
Packed cell volume of infusion 2 (ml)23.5n/an/a
AST peak post-dose 1 (day of peak) (units/l)653 (day 1)69 (day 4)168 (day 1)101 (day 5)
AST peak post-dose 2 (day of peak) (units/l)97 (day 1)1,031 (day 1)NANA
AST at time of imaging (units/l)68483029
ALT at time of imaging (units/l)60432344
Total bilirubin at time of imaging (mg/dl)0.30.80.30.4
Daily insulin dose at time of imaging (units)0057
Fasting C-peptide at time of imaging (ng/ml)1.21.51.30.7
Stimulated C-peptide at time of imaging (ng/ml)4.12.721.9
HbA1c at time of imaging (%)5.66.97.16.7
Mean tacrolimus trough levels (range) (mg/l)*4.93.2 (2.1–4.6)5.6 (3.2–7.7)3.2 (1.6–5.5)
Mean rapamycin trough levels (range) (mg/l)*12.310.5 (7.1–13.6)10.8 (9.7–15.1)8.8 (7.0–10.3)
Peak portal pressure rise with dose 1 (mmHg)1544
Peak portal pressure rise with dose 2 (mmHg)31NANA
  • *

    * Mean (and range) of last seven measurements prior to imaging study;

  • peak rise from baseline measured prior to beginning infusion. ALT, alanine aminotransferase; AST, aspartate aminotransferase.